SYNB2081 is the second clinical drug candidate
developed through the partnership between Ginkgo and
Synlogic
CAMBRIDGE, Mass. and BOSTON, Aug. 11,
2022 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a
clinical-stage biotechnology company developing medicines for
metabolic and immunological diseases through its proprietary
approach to synthetic biology, today announced a new drug candidate
for the treatment of gout developed in partnership with Ginkgo
Bioworks (NYSE: DNA), the leading horizontal platform for cell
programming. The new candidate, SYNB2081, is a Synthetic Biotic and
is the second product to advance to clinical development through a
research collaboration between Synlogic and Ginkgo, following the
investigational new drug candidate SYNB1353 for the potential
treatment of homocystinuria (HCU).
Gout is a complex form of inflammatory arthritis that occurs
when excess uric acid in the body forms crystals in the joints.
Patients experience symptoms such as intense joint pain,
inflammation and redness, and limited range of motion in the
affected joints. Current treatment options present limitations in
both safety and efficacy, highlighting a need for new approaches.
In addition, gout is a recognized risk factor in chronic kidney
disease. SYNB2081 is a Synthetic Biotic designed to lower uric
acid.
"With our second drug candidate into clinical development, this
not only demonstrates the value of combining Ginkgo's platform with
our Synthetic Biotic platform, but also highlights the potential to
develop Synthetic Biotics across a range of diseases, giving us the
potential to provide meaningful new treatment options to patients
in need," said Dr. David Hava, Chief
Scientific Officer, Synlogic.
SYNB2081 is named after one of the largest and best-preserved
Tyrannosaurus rex specimens in the world. Nicknamed "Sue," the
specimen is housed at the Field Museum in Chicago and is officially named FMNH PR 2081.
Data from "Sue" suggests that dinosaurs like the Tyrannosaurus rex
suffered from gout much in the same way as other reptiles and birds
do.
"The advancement of SYNB2081 and SYNB1353 are clear indicators
of the transformative platform Synlogic has created to develop new
Synthetic Biotics through synthetic biology," said Patrick Boyle, Head of Codebase for Ginkgo.
"We're honored to work with the Synlogic team in this pioneering
next step to potentially help patients living with gout. As we've
seen the Synlogic pipeline develop over the past year, we're eager
to continue supporting Synlogic in generating additional
therapeutic candidates."
About Synlogic
Synlogic is a clinical-stage biotechnology company
developing medicines through its proprietary approach to synthetic
biology. Synlogic's pipeline includes its lead program in
phenylketonuria (PKU), which has demonstrated proof of concept with
plans to start a pivotal, Phase 3 study in the first half of 2023,
and additional novel drug candidates designed to treat
homocystinuria (HCU) and enteric hyperoxaluria. The rapid
advancement of these potential biotherapeutics, called Synthetic
Biotics, has been enabled by Synlogic's reproducible,
target-specific drug design. Synlogic uses programmable,
precision genetic engineering of well-characterized probiotics to
exert localized activity for therapeutic benefit, with a focus on
metabolic and immunologic diseases. In addition to its clinical
programs, Synlogic has a research collaboration with
Roche on the discovery of a novel Synthetic Biotic for the
treatment of inflammatory bowel disease. Synlogic has also
developed two drug candidates through a research collaboration with
Ginkgo Bioworks: SYNB1353, designed to consume methionine for the
potential treatment of HCU, and SYNB2081, designed to lower uric
acid for the potential treatment of gout. For additional
information visit www.synlogictx.com.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program
cells as easily as we can program computers. The company's platform
is enabling biotechnology applications across diverse markets, from
food and agriculture to industrial chemicals to pharmaceuticals.
Ginkgo has also actively supported a number of COVID-19 response
efforts, including K-12 pooled testing, vaccine manufacturing
optimization and therapeutics discovery. For more information,
visit www.ginkgobioworks.com.
Forward-Looking Statements of
Synlogic
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, clinical development plans, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. In addition, when or
if used in this press release, the words "may," "could," "should,"
"anticipate," "believe," "look forward," "estimate," "expect,"
"intend," on track," "plan," "predict" and similar expressions and
their variants, as they relate to Synlogic, may identify
forward-looking statements. Examples of forward-looking statements,
include, but are not limited to, statements regarding the potential
of Synlogic's approach to Synthetic Biotics to develop therapeutics
to address a wide range of diseases including: inborn errors of
metabolism and inflammatory and immune disorders; our expectations
about sufficiency of our existing cash balance; the future clinical
development of Synthetic Biotics, including SYNB2081; the approach
Synlogic is taking to discover and develop novel therapeutics using
synthetic biology; and the expected timing of Synlogic's clinical
trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and
availability of clinical trial data. Actual results could differ
materially from those contained in any forward-looking statements
as a result of various factors, including: the uncertainties
inherent in the clinical and preclinical development process; the
ability of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the U.S Securities and Exchange
Commission. The forward-looking statements contained in this press
release reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However, while
Synlogic may elect to update these forward-looking statements in
the future, Synlogic specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing Synlogic's view as of any date subsequent to the date
hereof.
Forward-Looking Statements of
Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the potential success of the partnership and
Ginkgo's cell programming platform. These forward-looking
statements generally are identified by the words "believe," "can,"
"project," "potential," "expect," "anticipate," "estimate,"
"intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely
result," and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the effect of Ginkgo's business combination with
Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's
business relationships, performance, and business generally, (ii)
risks that the business combination disrupts current plans of
Ginkgo and potential difficulties in Ginkgo's employee retention,
(iii) the outcome of any legal proceedings that may be instituted
against Ginkgo related to its business combination with Soaring
Eagle, (iv) volatility in the price of Ginkgo's securities now that
it is a public company due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Ginkgo operates and plans to operate, variations in performance
across competitors, changes in laws and regulations affecting
Ginkgo's business and changes in the combined capital structure,
(v) the ability to implement business plans, forecasts, and other
expectations after the completion of the business combination, and
identify and realize additional opportunities, (vi) the risk of
downturns in demand for products using synthetic biology, (vii) the
unpredictability of the duration of the COVID-19 pandemic and the
demand for COVID-19 testing and the commercial viability of our
COVID-19 testing business, (viii) changes to the biosecurity
industry, including due to advancements in technology, emerging
competition and evolution in industry demands, standards and
regulations, and (ix) our ability to close and realize the expected
benefits of pending merger and acquisition transactions. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the "Risk Factors" section of Ginkgo's
quarterly report on Form 10-Q filed with the U.S. Securities and
Exchange Commission (the "SEC") on May 16,
2022 and other documents filed by Ginkgo from time to time
with the SEC. These filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Ginkgo assumes no obligation and
does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. Ginkgo does not give any assurance that it will
achieve its expectations.
SYNLOGIC MEDIA CONTACT:
Bill Berry
Berry & Company Public Relations
212-253-8881; bberry@berrypr.com
SYNLOGIC INVESTOR CONTACT:
Andrew Funderburk
Kendall Investor Relations
617-914-0008; afunderburk@kendallir.com
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/synlogic-announces-synthetic-biotic-for-gout-developed-in-partnership-with-ginkgo-bioworks-301603915.html
SOURCE Ginkgo Bioworks